A little-known biotech firm focused on Traditional Chinese Medicine has surged over 64,000%, catapulting its valuation to nearly $10 billion. Is this a biotech breakthrough, a speculative frenzy, or something in between?
Join Dan Koh and Ryan Huang as they dissect the rise of Regencell Bioscience Holdings Limited — a company with just 12 employees, no FDA-approved products, and a CEO earning $1 a year.

Companies To Watch: Exxon Mobil rallies as Middle East tensions send oil prices higher
10:37

Morning Shot: Why Preventable Cancer Risks Still Persist in Singapore
10:42

Bigger Pic: Crude Shocks and Central Bank Cracks
08:08